We hypothesize that NACT-induced reduction in tumor proliferation is prognostic for better outcome and that GEAs can overcome IHC-related technical and analytical challenges in assessing tumor proliferation status, providing a more precise and reproducible assessment of tumor proliferation to guide response-adapted therapy in ER+/HER2- breast cancer. This evidence concerns the gene ESR1 and breast cancer.